Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by <i>Staphylococcus</i> spp. and Vancomycin-Resistant Enterococci

Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by <i>Staphylococcus</i> spp. and Vancomycin-Resistant Enterococci

One approach to combat the increasing incidence of multidrug-resistant (MDR) bacterial pathogens involves repurposing existing compounds with known safety and development pathways as new antibacterial classes with potentially novel mechanisms of action. Here, triclabendazole (TCBZ), a drug originall...

Full description

Bibliographic Details
Main Authors: Hongfei Pi, Abiodun D. Ogunniyi, Bhumi Savaliya, Hang Thi Nguyen, Stephen W. Page, Ernest Lacey, Henrietta Venter, Darren J. Trott
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Microorganisms
Subjects:
multidrug resistance
triclabendazole
polymyxin B
bacterial pathogens
bioluminescence
sepsis
Online Access:https://www.mdpi.com/2076-2607/9/8/1697

Similar Items

Similar Items